RecruitingMajor Depressive Disorder (MDD)
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
Eligible age
18–70 yrs
Accepts
All genders
Locations
20 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder
Sponsor: Supernus Pharmaceuticals, Inc.
You may qualify if…
- ✓ Current diagnosis of MDD according to the DSM-5 for either single or recurrent MDE without psychotic features confirmed by the MINI
- ✓ Duration of current MDE of at least 8 weeks
- ✓ MADRS total score of ≥ 24 at the Screening Visit and Day 1 Visit
- ✓ CGI-S score of ≥ 4 (moderately ill or worse) at the Screening Visit and Day 1 Visit
- ✓ Stable, therapeutic dose of one of the following protocol-approved ADTs as a monotherapy for ≥ 8 weeks before the Screening Visit and ≥ 10 weeks at the Day 1 Visit. Additionally, inadequate response to the current ADT (less than 50% improvement in depressive symptoms) as confirmed by the ATRQ Investigator administered.
You may not qualify if…
- ✕ MADRS total score change of ≥ 25% from the Screening Visit to Day 1 Visit
- ✕ History of treatment resistant depression (TRD) defined as 3 or more failed ADTs of adequate dose (per ATRQ) and duration (at least 8 weeks) for the current MDE
- ✕ History of alcohol or substance use disorder according to DSM-5 criteria 6 months before the Screening Visit
- ✕ Evidence of significant risk for suicidal behavior during participation in the study in the Investigator's opinion
- ✕ Lifetime diagnosis of any psychotic disorder including MDD with psychosis, MDD with mixed features, bipolar I/II disorder, bipolar depression, schizophrenia, posttraumatic stress disorder, autism spectrum disorder, or any personality disorder or intellectual disability that would affect the ability of the participant to enroll in the study
- ✕ Diagnosis less then 12 months before screening of severe obsessive-compulsive disorder, acute stress disorder, panic disorder, eating disorders, or any other psychiatric condition that has been the primary focus of treatment, or diagnosis of generalized anxiety disorder less then 6 months before screening.
- ✕ History of cardiovascular, respiratory, gastrointestinal, renal, hepatic, and hematologic disorders, or other medical disorders that could impose undue risk or compromise the study in the Investigator's opinion
- ✕ Clinically significant abnormal result prior to Day 1 Visit per Investigator's judgment or abnormal renal function.
Where it's recruiting
Alabama
Birmingham
Arizona
Phoenix
Arkansas
Rogers
California
Chino · Encino · Garden Grove · Lemon Grove …
Colorado
Denver
Connecticut
Cromwell
Florida
Jacksonville · Miami · Orlando · Palm Bay …
Georgia
Atlanta · Decatur
Illinois
Warrenville
Mississippi
Flowood
Missouri
O'Fallon · Saint Charles
Nevada
Las Vegas
Source: ClinicalTrials.gov · NCT07226661 · last updated 2026-11-16